MKI67 and ovarian cancer: Immunohistochemical analysis of Ki-67 in tumor tissues in the control group and the SORBS2 knockdown group did not demonstrate significant difference (Additional file 2: Figure S8a), indicating that SORBS2 knockdown primarily hijacked metastatic programs instead of proliferation-related signaling in ovarian cancer.